While traditional approaches involve diet, exercise, medication, and sometimes bariatric surgery, many individuals struggle to achieve and maintain significant weight loss due to factors like persistent food cravings, emotional eating, and metabolic dysregulation. 

Studies suggest that Deep TMS may influence brain regions involved in appetite control, reward pathways (e.g., dopaminergic system), and impulsivity, which are critical in regulating eating behaviors and satiety. 

Some preliminary findings indicate that targeted Deep TMS could potentially help in reducing food cravings, influencing satiety, and contributing to weight loss for some individuals by modulating these neural circuits.

You are viewing a page that is not intended for persons in the United States, and includes information about treatment applications that HAVE NOT BEEN CLEARED by the FDA for safety and efficacy.

However, BrainsWay Deep TMS™ has received the European CE Mark for the treatment of many conditions.

This significant approval underscores the therapy's established safety and efficacy for these indications in Europe. While regulatory statuses vary by region, this CE Mark highlights the recognized potential of Deep TMS as a therapeutic option for:

Major Depressive Disorder (MDD)

Anxiety Depression

Obsessive-Compulsive Disorder (OCD)

Smoking Cessation

Alzheimer's Disease (AD)

Autism

Bipolar Disorder

Chronic Pain

Multiple Sclerosis (MS)

Parkinson's Disease

Post-Stroke Rehabilitation

Post-Traumatic Stress Disorder (PTSD)

Negative Symptoms of Schizophrenia